Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Study of long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue BTK inhibitor treatment finds median PFS 71.9 mos (95% CI, 51.5–97.8), 5-year PFS 57%, time to next treatment of 38.3 months.”
Title: Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy
Authors: Karan L. Chohan, Lorenzo Gensini, Sherif Seif, Xiaowen Sun, Lei Feng, Melody R. Becnel, Mahmoud M. Gaballa, Hans C. Lee, Oren Pasvolsky, Krina K. Patel, J. Christine Ye, Donna M. Weber, Robert Z. Orlowski, Sheeba K. Thomas
You can read the Full Article in Blood Cancer Journal.
You can find more posts featuring Robert Orlowski on OncoDaily.
